Aptuit To Acquire EaglePicher Pharmaceutical Services

September 28, 2006
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Aptuit, Inc. (Greenwich, CT) has agreed to acquire the assets and operations of EaglePicher Pharmaceutical Services (EPPS, Lenexa, KS) as part of Aptuit?s strategies to build capabilities in active pharmaceutical ingredient (API) development and drug substance manufacturing.

Greenwich, CT (Sept. 26)––Aptuit, Inc. (Greenwich, CT, www.aptuit.com) agreed to acquire the assets and operations of EaglePicher Pharmaceutical Services (EPPS, Lenexa, KS, www.eaglepicher.com) as part of Aptuit’s strategy to build capabilities in active pharmaceutical ingredient (API) development and drug substance manufacturing.

Aptuit will acquire EaglePicher’s facilities in Lenexa, Kansas and Harrisonville, Missouri and plans further investments. “We intend to make significant investments in our new API operation over the next 18 months to upgrade the EPPS Harrisonville facility, extend its range of capabilities, and improve its regulatory profile,” said Michael A. Griffith, CEO of Aptuit, in a company release. “Additionally, we will be building a first-class lab-based process-development and kilo-lab capability.”

The acquisition extends Aptuit’s capabilities to include API supply from post discovery to market. Following the acquisition, Aptuit will have 12 facilities globally, including a clinical trial distribution network of 27 supply depots. The acquisition is expected to close within 90 days.

Related Content:

PharmTech News | Manufacturing